

***Remarks***

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 1 and 73-89 are pending in the application, with claims 1 and 73 being the independent claims. Claim 1 is sought to be amended. Claims 73-89 are sought to be added. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Based on the above amendment and the following remarks, Applicants respectfully request that the Examiner reconsider all outstanding rejections and that they be withdrawn.

***I. Support for Amended and New Claims***

Support for amended claim 1 and new claims 73 and 74 can be found throughout the specification, for example, at page 22, lines 6-15.

Support for new claims 75-89 can be found throughout the specification, for example, in originally presented claims 2, 3, 12-19 and 36-40, respectively.

***II. Claim Rejections Under 35 U.S.C. § 102***

Claim 1 was rejected under 35 U.S.C. § 102(b) as being anticipated by Nishi *et al.*, *In Vitro Cell. Dev. Biol.* 24:778-786 (1988) ("Nishi"), Sakthivel *et al.*, *Cell Biol. Int.* 17:387-397 (1993) ("Sakthivel"), Yang *et al.*, *Exp. Cell. Res.* 137:481-485 ("Yang"), or Turner *et*

*al.*, *In Vitro Cell. Dev. Biol.* 26:722-730 (1990) ("Turner"). Applicants respectfully submit that the currently presented claims are not anticipated by any of the cited documents.

The currently presented claims are directed to serum-free cell culture media comprising a fibroblast growth factor (FGF) and an agent causing an increase in intracellular levels of cyclic adenosine monophosphate (cAMP). For claims 1 and 75-89, the agent that causes an increase in intracellular levels of cAMP is selected from the group consisting of forskolin, isoproterenol and theophylline. For claim 73, the agent is a  $\beta$ -adrenergic receptor agonist, and for claim 74, the agent ( $\beta$ -adrenergic receptor agonist) is isoproterenol.

An anticipation rejection under 35 USC § 102 requires a showing that each limitation of a claim is found in a single reference, practice, or device. *See In re Donohue*, 766 F.2d 531, 226 USPQ 619, 621 (Fed. Cir. 1985). None of the cited references teaches a serum-free cell culture medium comprising an FGF and an agent that causes an increase in intracellular levels of cAMP as specified in the claims. In fact, none of the references mentions forskolin or theophylline at all. Yang is the only reference that mentions isoproterenol, but isoproterenol is never combined in a culture medium with an FGF in this reference.

Therefore, the cited references do not anticipate the present claims. Applicants respectfully request that this rejection be reconsidered and withdrawn.


***Conclusion***

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham  
Attorney for Applicants  
Registration No. 50,437

Date: June 9, 2004

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600